ACE Report Cover
Antifibrinolytic agents reduce blood loss and transfusion requirements in spine surgery
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Lingua
Download Download Download
Scaricare
Cite this Report Cite this Report Cite this Report
Citare
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Preferiti
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Lingua
Download Download Download
Scaricare
Cite this Report Cite this Report Cite this Report
Citare
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Preferiti
SPINE
Antifibrinolytic agents reduce blood loss and transfusion requirements in spine surgery .

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2014;2(3):23 PLoS One. 2013 Nov 22;8(11):e82063
Autori che hanno contribuito

C Yuan H Zhang S He

9 randomized controlled studies, with a total of 664 patients, were included in this meta-analysis to compare antifibrinolytic agents such as tranexamic acid (TXA) and epsilonaminocaproic acid (EACA), to a placebo in regards to blood loss, transfusion requirements and deep vein thrombosis incidence in patients who underwent spine surgery. The antifibrinolytic agents were effective in reducing total blood loss, total blood transfusion and ratio of blood transfusion; additionally, the incidence of deep vein thrombosis was comparable between the antifibrinolytic agents and the placebos used.


Dettagli sul finanziamento della pubblicazione +
Finanziamento:
Non-funded
Conflicts:
None disclosed

Rischio di pregiudizio

10/10

Criteri di segnalazione

19/20

Indice di fragilità

N/A

Were the search methods used to find evidence (original research) on the primary question or questions stated?

Was the search for evidence reasonably comprehensive?

Were the criteria used for deciding which studies to include in the overview reported?

Was the bias in the selection of studies avoided?

Were the criteria used for assessing the validity of the included studies reported?

Was the validity of all of the studies referred to in the text assessed with use of appropriate criteria (either in selecting the studies for inclusion or in analyzing the studies that were cited)?

Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?

Were the findings of the relevant studies combined appropriately relative to the primary question that the overview addresses?

Were the conclusions made by the author or authors supported by the data and or analysis reported in the overview?

How would you rate the scientific quality of this evidence?

Sì = 1

Incerto = 0,5

Non rilevante = 0

No = 0

La valutazione dei criteri di segnalazione valuta la trasparenza con cui gli autori riportano le caratteristiche metodologiche e sperimentali dello studio all'interno della pubblicazione. La valutazione è suddivisa in cinque categorie che vengono presentate di seguito.

4/4

Introduction

4/4

Accessing Data

4/4

Analysing Data

4/4

Results

3/4

Discussion

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

L'Indice di Fragilità è uno strumento che aiuta l'interpretazione dei risultati significativi, fornendo una misura della forza di un risultato. L'Indice di Fragilità rappresenta il numero di eventi consecutivi che devono essere aggiunti a un risultato dicotomico per rendere il risultato non più significativo. Un numero piccolo rappresenta un risultato più debole, mentre un numero grande rappresenta un risultato più forte.

Perché questo studio era necessario ora?

Spine surgery, particularly multilevel spinal fusion, deformity correction and anterior-posterior spinal fusion, are associated with significant blood loss and transfusion requirements. Transfusions can be the cause of a variety of complications which can be decreased with autologous blood donations, application of cell saver-systems or the use of erythropoietin; however, these solutions are expensive and logistically challenging. Intraoperative administration of antifibrinolytics such as tranexamic acid (TXA), epsilonaminocaproic acid (EACA) and aprotinin are becoming more popular in spine surgery. Recent high-quality evidence provides reason to conduct a current meta-analysis on the topic; therefore, this study was conducted to determine the effects of antifibrinolytic agents on reducing perioperative blood loss in spine surgery.

Qual era la domanda di ricerca principale?

What are the effects of antifibrinolytic agents such as tranexamic acid (TXA) and epsilonaminocaproic acic (EACA) on perioperative blood loss and transfusion requirements in patients undergoing spine surgery?

Caratteristiche dello studio +
Data Source:
The search was performed using MEDLINE, EMBASE and the Cochrane Library databases for all studies written in English published by October 2012. WHO International Clinical Trials Registry Platform, UK National Research Register Archive and Current Controlled Trials from their inception to October 2012 for unpublished trials. All reference lists were searched for relevant articles.
Index Terms:
Spine surgery, spinal surgery, antifibrinolytic agents, tranexamic acid, and epsilonaminocaproic acid
Study Selection:
9 randomized controlled trials that compared TXA or EACA to a placebo in spine surgery and reported on at least one of blood loss, blood transfusion, ratio of blood transfusion, or incidence of deep vein thrombosis (DVT) were independently selected by two reviewers; discrepancies were resolved through discussion.
Data Extraction:
Data extraction of authors, year of publication, country, sample size, age, gender, drug dosage, transfusion indication, duration of surgery, total blood loss, blood transfusion, ratio of blood transfusion, and incidence of DVT.
Data Synthesis:
Data analyses were performed with Review Manager Version 5.2. Continuous outcomes were pooled as weight mean difference (WMD) with 95% confidence intervals (CI) and risk ratios (RR) with 95% CIs were used to evaluate dichotomous data. Significant outcomes had a p value of less than 0.05. A fixed-effects model was used for data that was not significantly heterogeneous (p>0.05) and a random-effects model was used significantly heterogeneous data (p<0.05).
Quali erano i risultati importanti?
  • 8 studies reported on total blood loss, the overall effect was significantly different in favour of the intervention (WMD =-288.8, 95 % CI -46.49 to -110.19; p = 0.002).Subgroup analyses of 6 studies that examined TXA and 2 studies evaluating EACA resulted in similar conclusions (WMD =-285.3, 95 % CI -506.99 to -63.65; p = 0.01 and WMD =-338.1, 95 % CI -583.03 to -93.33; p = 0.007, respectively).
  • The 9 studies that reported on total blood transfusion and found a significant difference in favour of antifibrinolytic agents(WMD =-242.76, 95 % CI -422.5 to -62.95; p = 0.008). Subgroup analysis of 6 studies involving TXA indicated significant differences in favour of TXA (WMD=-242.76, 95 % CI -422.5 to -62.95; p = 0.008) and 3 studies display improved results with EACA as well compared to a placebo (WMD =-358.1, 95 % CI -608.49 to -107.71; p = 0.005)
  • Ratio of blood transfusion was available in 7 studies and overall antifibrinolytic agents proved superior over the placebo (RR = 0.73, 95% CI 0.58 to 0.93; p = 0.010). A subgroup analysis of TXA alone resulted in similar findings (RR =0.71, 95 % CI 0.54 to 0.92; p= 0.01).
  • 9 Studies examined the DVT incidence and found no difference between groups (RR 0.25, 95 % CI 0.03 to 2.22; p= 0.21).
Che cosa devo ricordare di più?

The antifibrinolytic agents tranexamic acid (TXA) and epsilonaminocaproic acid (EACA) were both effective in reducing total blood loss, total blood transfusion and ratio of blood transfusion. The incidence of deep vein thrombosis was comparable between the antifibrinolytic agents and the placebos used.

Come influenzerà l'assistenza ai miei pazienti?

Results of this study suggest that patients undergoing spine surgery can benefit from the administration of antifibrinolytic agents such as tranexamic acid and epsilonaminocaproic acid in terms of reducing blood loss and transfusion requirements. This study was limited by the small sample sizes of the included trials and the heterogeneity in variation in drug dose, surgical procedure, operation time, age of patients, protocol for estimating blood loss and transfusion indication. All of the included studies featured intravenous administration of the study drugs; whether there is a role of topical agents in spine surgery remains to be determined.

DISCLAIMER

Il contenuto di questa pagina è solo a scopo informativo e non intende sostituire la consulenza, la diagnosi o il trattamento medico professionale. Se ha bisogno di cure mediche, si rivolga sempre al suo medico o al pronto soccorso più vicino. Le opinioni, le convinzioni e i punti di vista espressi dalle persone sui contenuti presenti in questa pagina non riflettono le opinioni, le convinzioni e i punti di vista di OrthoEvidence.

0 di 4 articoli mensili GRATUITI sbloccati
Ha raggiunto il suo limite di 4 visualizzazioni di articoli gratuiti questo mese

Accesso a OrthoEvidence a soli 1,99 dollari a settimana.

Rimanga in contatto con le ultime prove. Può disdire in qualsiasi momento.
  • Valutazioni critiche dei più recenti studi randomizzati controllati ad alto impatto e delle revisioni sistematiche in ortopedia.
  • Accesso ai contenuti del podcast OrthoEvidence, tra cui collaborazioni con il Journal of Bone and Joint Surgery, interviste con chirurghi di fama internazionale e tavole rotonde su notizie e argomenti ortopedici.
  • Abbonamento a The Pulse, una newsletter bisettimanale basata sulle evidenze scientifiche, progettata per aiutarla a prendere decisioni cliniche migliori.
Upgrade
Bentornato!
Ha dimenticato la password?
Inizi la sua prova gratuita oggi stesso!

Il suo account sarà affiliato a
e includerà l'accesso gratuito a OrthoEvidence


O
Ha dimenticato la password?

O
Controlli la sua e-mail

Se esiste un account con l'indirizzo e-mail fornito, le verrà inviata un'e-mail di reimpostazione della password. Se non vede l'e-mail, controlli la cartella spam o posta indesiderata.

Per ulteriore assistenza, contatti il nostro team di supporto.

Effettui il login per abilitare questa funzione

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence attivo. Effettui il login o crei un account di prova GRATUITO.

Tradurre il Rapporto ACE

OrthoEvidence utilizza un servizio di traduzione di terze parti per rendere i contenuti accessibili in più lingue. Si prega di notare che, sebbene venga fatto ogni sforzo per garantire l'accuratezza, le traduzioni potrebbero non essere sempre perfette.

Come citare questo documento ACE Report

OrthoEvidence. Antifibrinolytic agents reduce blood loss and transfusion requirements in spine surgery. OE Journal. 2014;2(3):23. Available from: https://myorthoevidence.com/AceReport/Show/antifibrinolytic-agents-reduce-blood-loss-and-transfusion-requirements-in-spine-surgery

Copiare la citazione
Effettui il login per abilitare questa funzione

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence attivo. Effettui il login o crei un account di prova GRATUITO.

Funzionalità per i membri Premium

Per accedere a questa funzione, deve essere collegato ad un account OrthoEvidence Premium.

Condividi questo articolo ACE Report